A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Bristol-Myers Squibb (BMS)

Status: Active, not recruiting

Conditions: Hypertrophic Cardiomyopathy

Treatments: Drug: Mavacamten

Study type: Observational

Funder types: Industry

Identifiers

NCT06549608

CV027-1187

Details and patient eligibility

About

This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored CAMZYOS Patient Support Program in Canada.

Enrollment: 685 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants ≥18 years of age.
• Participants who have initiated mavacamten as part of routine clinical care, through the BMS-sponsored CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
• Participants who consented to the use of their de-identified data, generated from information collected in the course of the program.

Exclusion criteria

• There are no exclusion criteria.

Trial design

685 participants in 1 patient group

Adults participants treated with mavacamten

Description:

Participants with symptomatic obstructive hypertrophic cardiomyopathy (NYHA functional class II-III) who receive mavacamten as part of routine clinical care.

Treatment:

Drug: Mavacamten